SYRE Insider Trading Activity and SEC Form 4 Filings
SYRE insider trading summary
Over the past 12 months, insiders at Spyre Therapeutics, Inc. (SYRE) reported 97 sales worth $1.64B by 10 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.64B.
Latest SYRE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Cameron Turtle | Chief Executive Officer | Sell | $368K (3,989 @ $92.31) |
| Oct 1, 2026 | Cameron Turtle | Chief Executive Officer | Sell | $241K (2,638 @ $91.49) |
| Oct 1, 2026 | Cameron Turtle | Chief Executive Officer | Sell | $242K (2,683 @ $90.10) |
| Oct 1, 2026 | Scott L Burrows | Chief Financial Officer | Sell | $193K (2,100 @ $91.92) |
| Oct 1, 2026 | Cameron Turtle | Chief Executive Officer | Sell | $53K (600 @ $89.14) |
| Oct 1, 2026 | Scott L Burrows | Chief Financial Officer | Sell | $21K (229 @ $93.57) |
| Oct 1, 2026 | Scott L Burrows | Chief Financial Officer | Sell | $53K (600 @ $89.07) |
| Oct 1, 2026 | Scott L Burrows | Chief Financial Officer | Sell | $285K (3,071 @ $92.95) |
| Oct 1, 2026 | Scott L Burrows | Chief Financial Officer | Sell | $135K (1,500 @ $90.27) |
| Oct 1, 2026 | Cameron Turtle | Chief Executive Officer | Sell | $466K (4,990 @ $93.37) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.